IQVIA to Build Clinically-Focused Tech Solutions Suite for Life Sciences on Salesforce Health Cloud
September 20 2018 - 8:00AM
Business Wire
IQVIA (NYSE: IQV) today announced the expansion of its
alliance with Salesforce, the global leader in CRM and
provider of Software as a Service (SaaS) solutions, to build a
clinical solution for life sciences on Salesforce Health Cloud.
IQVIA’s suite of clinical technology solutions can speed clinical
trials, while reducing patient burden, with the ultimate goal of
advancing human health.
“We are proud of this strategic collaboration with IQVIA’s
technology capabilities and the important role that Salesforce will
have in accelerating clinical innovation,” said Tyler Prince, EVP,
Industries and Partners, Salesforce. “This is the next step in the
Salesforce and IQVIA commitment to accelerate life sciences
products more quickly through the entire product lifecycle.”
The clinical suite, which leverages IQVIA’s deep life sciences
expertise, includes both SaaS and technology-enabled services that
will automate study processes, drive R&D insights from
artificial intelligence and machine learning, and strengthen
connections between patients and clinicians.
The general components of this IQVIA expansion will include:
- A virtual trial technology platform
designed to coordinate research and workflows, support patient
communications, and efficiently capture study activity throughout
the patient journey.
- A new solution that brings healthcare
professionals, patients and studies together to help solve patient
enrollment challenges that can add tens of millions of dollars
every year to drug development costs.
- An innovative, patient-centric suite of
products that can work together or individually based on the unique
needs of every trial to drive efficiency and execution of
R&D.
“The solutions coming out of this latest phase of our alliance
with Salesforce are centered on the patient experience,” said
Richard Staub, president of IQVIA’s Research & Development
Solutions. “These innovations can help enable our customers to run
their clinical trials faster and smarter. By simplifying processes
and increasing agility, clients can create more personalized
provider and patient experiences during the clinical stage –
ultimately leading to better therapies, health outcomes, patient
access and commercial success at launch.”
The suite of clinical solutions will be designed to accelerate
research and trial safety, in addition to protecting patient
privacy while boosting patient participation, adherence and
convenience throughout the study.
“We are excited to build a suite of applications that will
enable an uninterrupted flow of study information and results,
while connecting clinical, regulatory, and compliance content to
the Orchestrated Customer Engagement solution on a common
Salesforce platform,” said Tal Rosenberg, senior vice president,
Global Technology Solutions at IQVIA.
While terms of the agreement have not been disclosed, it is a
multi-year alliance that will operate on a global scale.
Salesforce, Health Cloud and others are among the trademarks of
salesforce.com, inc.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing the information that helps its customers
drive human health outcomes forward. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical
companies, medical researchers, government agencies, payers, and
other healthcare stakeholders tap into a deeper understanding of
diseases, human behaviors, and scientific advances, in an effort to
advance their path toward cures. To learn more, visit
www.iqvia.com.
Click here to subscribe to Mobile Alerts for IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180920005128/en/
IQVIAMedia Relations:Tor Constantino,
+1-484-567-6732tor.constantino@iqvia.comorInvestor Relations:Andrew
Markwick, +1-973-257-7144andrew.markwick@iqvia.com
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jul 2023 to Jul 2024